Incidence of Helicobacter Pylori Infections and Therapy for Anastomotic ulcers and Residual Gastritis in Patients with Residual Stomachs.
Seventy-seven patients with the vestibular portion of their stomachs resected (residual stomach) due to ulcers or stomach cancers were included in this study. Fifty-five (71.4%) of these patients had Helicobacter pylori infections. H. pylori was found in all patients with stomach cancer, esophageal cancer, or esophageal venous varicosity, and in 86.7% of patients with esophagitis, 78.6% with residual gastritis, 70.0% with anastomotic ulcers, and in 51.6% of patients with normal mucosa in their resected stomachs. The in vitro antibacterial activities of amoxicillin, erythromycin, clarithromycin, minocycline, nalidixic acid, ofloxacin, lansoprazole, and omeprazole were determined against 10 clinical isolates of H. pylori. All agents except ofloxacin, nalidixic acid and omeprazole showed satisfactory bactericidal activities. The clinical and bacteriological efficacies of a combined treatment regimen with lansoprazole and clarithromycin were evaluated in 10 patients with anastomotic ulcers and 6 patients with residual stomach inflammation after informed consent. The clinical efficacy of this treatment in these 16 patients was excellent for 3 patients, good for 12 patients, and fair for the other patient. Collectively, the treatment was effective in 15/16 (93.8%) of patients. The bacteriological efficacy of this treatment regimen was evaluated in 14 patients, with no evidence of H. pylori 13 (92.9%) patients.